Merck & Co doubles up on Ablynx research deal


Cut-down antibody drug developer Ablynx has agreed a second R&D partnership with US Pharma firm Merck & Co. Ablynx will receive €20 million (£17 million) up front, plus up to €10.7 million in research funding over three years. On top of that, milestone payments for any products that emerge from the collaboration could net the Belgian biotech up to €1.7 billion plus royalties.

This collaboration will focus on nanobodies (antibody fragments) directed against cancer, and builds on Merck’s previous collaboration with Ablynx for nanobodies that target voltage-gated ion channels. Ablynx also recently joined forces with Abbvie to develop nanobodies for treating rheumatoid arthritis and systemic lupus erythematosus.


Related Content

Merck & Co $460m ion channel deal

2 October 2012 Business

news image

Deal with Ablynx relates to antibody fragments

Business roundup

27 April 2011 Business

news image

Industry news, May 2011

Most Read

Complex amines made easy (and cheap)

22 May 2015 Research

news image

Iron-catalysed cross-coupling brings together nitroarenes and olefins in a single step in boon for drug makers

Opiate-producing yeast raises spectre of 'home-brewed heroin'

18 May 2015 News and Analysis

news image

Warnings that completion of final steps in opiate biosynthesis could be a double-edged sword

Most Commented

The nuclear danger of iodine

20 May 2015 Comments

news image

It may not be an element you think of as problematic. But, as Mark Foreman explains, iodine causes very complicated problems ...

Opiate-producing yeast raises spectre of 'home-brewed heroin'

18 May 2015 News and Analysis

news image

Warnings that completion of final steps in opiate biosynthesis could be a double-edged sword